vs
KKR Real Estate Finance Trust Inc.（KREF）与SCYNEXIS INC（SCYX）财务数据对比。点击上方公司名可切换其他公司
KKR Real Estate Finance Trust Inc.的季度营收约是SCYNEXIS INC的1.4倍（$25.8M vs $18.6M），SCYNEXIS INC净利率更高（65.7% vs -101.7%，领先167.5%），SCYNEXIS INC同比增速更快（1808.5% vs -26.6%），过去两年SCYNEXIS INC的营收复合增速更高（268.5% vs -18.8%）
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
SCYNEXIS是一家生物科技企业，专注于研发创新抗真菌疗法，用于治疗难治性真菌感染，满足未被覆盖的医疗需求，主要面向医院及专科护理市场，核心产品管线覆盖免疫低下患者等高危人群。
KREF vs SCYX — 直观对比
营收规模更大
KREF
是对方的1.4倍
$18.6M
营收增速更快
SCYX
高出1835.1%
-26.6%
净利率更高
SCYX
高出167.5%
-101.7%
两年增速更快
SCYX
近两年复合增速
-18.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.8M | $18.6M |
| 净利润 | $-26.2M | $12.3M |
| 毛利率 | — | — |
| 营业利润率 | -105.1% | 56.3% |
| 净利率 | -101.7% | 65.7% |
| 营收同比 | -26.6% | 1808.5% |
| 净利润同比 | -229.6% | 376.5% |
| 每股收益（稀释后） | $-0.49 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KREFSCYX
| Q4 25 | $25.8M | $18.6M | ||
| Q3 25 | $25.3M | $334.0K | ||
| Q2 25 | $30.2M | $1.4M | ||
| Q1 25 | $31.3M | $257.0K | ||
| Q4 24 | $35.1M | $977.0K | ||
| Q3 24 | $37.0M | $660.0K | ||
| Q2 24 | $40.4M | $736.0K | ||
| Q1 24 | $39.1M | $1.4M |
净利润KREFSCYX
| Q4 25 | $-26.2M | $12.3M | ||
| Q3 25 | $13.8M | $-8.6M | ||
| Q2 25 | $-29.7M | $-6.9M | ||
| Q1 25 | $-4.9M | $-5.4M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $-7.4M | $-2.8M | ||
| Q2 24 | $25.8M | $-14.5M | ||
| Q1 24 | $-3.1M | $411.0K |
营业利润率KREFSCYX
| Q4 25 | -105.1% | 56.3% | ||
| Q3 25 | 50.4% | -2516.5% | ||
| Q2 25 | -101.3% | -701.0% | ||
| Q1 25 | -18.3% | -3350.2% | ||
| Q4 24 | 55.8% | — | ||
| Q3 24 | -19.6% | -1563.6% | ||
| Q2 24 | 63.3% | -1255.0% | ||
| Q1 24 | -8.7% | -692.5% |
净利率KREFSCYX
| Q4 25 | -101.7% | 65.7% | ||
| Q3 25 | 54.4% | -2572.2% | ||
| Q2 25 | -98.5% | -504.8% | ||
| Q1 25 | -15.5% | -2097.7% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -20.0% | -425.5% | ||
| Q2 24 | 63.9% | -1964.4% | ||
| Q1 24 | -7.9% | 29.9% |
每股收益（稀释后）KREFSCYX
| Q4 25 | $-0.49 | $0.25 | ||
| Q3 25 | $0.12 | $-0.17 | ||
| Q2 25 | $-0.53 | $-0.14 | ||
| Q1 25 | $-0.15 | $-0.11 | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $-0.19 | $-0.06 | ||
| Q2 24 | $0.29 | $-0.30 | ||
| Q1 24 | $-0.13 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.6M | $40.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $49.4M |
| 总资产 | $6.5B | $59.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KREFSCYX
| Q4 25 | $84.6M | $40.0M | ||
| Q3 25 | $204.1M | $37.9M | ||
| Q2 25 | $107.7M | $44.8M | ||
| Q1 25 | $106.4M | $40.6M | ||
| Q4 24 | $104.9M | $59.3M | ||
| Q3 24 | $108.8M | $68.8M | ||
| Q2 24 | $107.2M | $73.0M | ||
| Q1 24 | $106.5M | $80.2M |
股东权益KREFSCYX
| Q4 25 | $1.2B | $49.4M | ||
| Q3 25 | $1.2B | $36.4M | ||
| Q2 25 | $1.2B | $44.5M | ||
| Q1 25 | $1.3B | $50.5M | ||
| Q4 24 | $1.3B | $55.1M | ||
| Q3 24 | $1.4B | $58.5M | ||
| Q2 24 | $1.4B | $60.4M | ||
| Q1 24 | $1.4B | $74.1M |
总资产KREFSCYX
| Q4 25 | $6.5B | $59.0M | ||
| Q3 25 | $6.5B | $51.1M | ||
| Q2 25 | $6.8B | $60.7M | ||
| Q1 25 | $6.6B | $67.9M | ||
| Q4 24 | $6.4B | $90.6M | ||
| Q3 24 | $6.8B | $99.0M | ||
| Q2 24 | $7.1B | $107.8M | ||
| Q1 24 | $7.3B | $118.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.3M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.50× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流KREFSCYX
| Q4 25 | $72.3M | $18.4M | ||
| Q3 25 | $18.5M | $-8.7M | ||
| Q2 25 | $21.1M | $-7.5M | ||
| Q1 25 | $15.9M | $-7.5M | ||
| Q4 24 | $132.6M | $-24.0M | ||
| Q3 24 | $49.1M | $765.0K | ||
| Q2 24 | $30.6M | $-10.9M | ||
| Q1 24 | $34.5M | $-4.0M |
现金转化率KREFSCYX
| Q4 25 | — | 1.50× | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | -9.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KREF
暂无分部数据
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
